The number of class-action lawsuits claiming securities fraud committed by life sciences companies climbed again last year, continuing a trend in which drug and device makers remain juicy targets for investors, according to a new analysis.

A total of 88 class action securities lawsuits were filed against life sciences companies in 2017, a 31 percent rise from the 67 lawsuits filed the year before and a 225 percent increase from 27 such lawsuits filed in 2012, according to the Dechert law firm, which conducted the latest analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy